NEXT-GENERATION RADIOIMMUNOTHERAPIES FOR NON-HODGKIN ... · NEXT-GENERATION RADIOIMMUNOTHERAPIES...
Transcript of NEXT-GENERATION RADIOIMMUNOTHERAPIES FOR NON-HODGKIN ... · NEXT-GENERATION RADIOIMMUNOTHERAPIES...
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
NEXT-GENERATION RADIOIMMUNOTHERAPIESFOR NON-HODGKIN’S LYMPHOMA PATIENTS
Forward-looking statementsThis slide presentation contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.This presentation is for information purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by the Company. The information and opinions in this presentation is provided as at the date hereof and subject to change without notice. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company’s financial or trading position or prospects. This presentation does not constitute investment, legal, accounting, regulatory, taxation or other advice and does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs. You are solely responsible for forming your own opinions and conclusions on such matters and for making your own independent assessment of the Company. You are solely responsible for seeking independent professional advice in relation to the Company. No responsibility or liability is accepted by any person for any of the information or for any action taken by you or any of your officers, employees, agents or associates on the basis of such information.
2
Corporate snapshot
• Founded 2009 in Oslo, Norway to develop Betalutin® for the treatment of non-Hodgkin’s lymphoma (NHL) based on
– The Norwegian Radium Hospital is a centre of excellence for oncology biomedical research and patient care
– R&D expertise in radioimmunotherapies
3
Nordic Nanovector is a clinical-stage biopharmaceutical company dedicated to extending
and improving the lives of patients with haematological cancers through the development
and commercialisation of innovative targeted radioimmunotherapies
• HQ and R&D in Oslo, with corporate offices in London, UK and Zug, Switzerland
• 47 Employees (around 60 FTEs in total)
• Listed on Oslo Stock Exchange in 2015 (NANO)
• Market cap USD 152M*
*As of August 23, 2019. Exchange rate 1 USD = 9,001202 NOK.
4
Management Team with international experience
JOSTEIN DAHLE, PhDCo-Founder, Chief Scientific Officer
MARCO RENOLDI, MDChief Operating Officer
LISA ROJKJAER, MDChief Medical Officer
TONE KVÅLEChief Financial Officer
RITA DEGEChief Human Resources Officer
MALENE BRONDBERGVice President, IR & Corporate Communications
ROSEMARIE CORRIGANChief Quality Officer
EDUARDO BRAVOChief Executive Officer
Nordic Nanovector – experts in radioimmunotherapy
5
Betalutin®
Fully owned lead asset – a novel anti-CD37 radioimmunotherapy targeting unmet needs in the two largest NHL types – FL and DLBCL – a near USD 5B* opportunity
A single administration of Betalutin® has demonstrated promising efficacy and safety in a 74-patient trial
Pivotal trial in 3L R/R FL underway with full enrolment expected 2H 2020; Fast-Track and Orphan Drug designations granted in US
R&D expertise and IP provides multiple opportunities in B-cell malignancies
On-going clinical programmes to access higher-value 2L FL and R/R DLBCL provide additional near-term value inflection points
FL – Follicular lymphoma; DLBCL – Diffuse large B-cell lymphoma: R/R – relapsed/refractory; 3L – 3rd line; 2L – 2nd line* Pharmacor Oncology: Non Hodgkin’s Lymphoma by Decision Resources Group, 2015
6
Candidate Targeted indication Discovery Preclinical Phase 1 Phase 2 Phase 3
Betalutin® 3L FL
Betalutin®
(combination w/RTX) 2L FL
Betalutin® R/R DLBCL (SCT ineligible)
Humalutin®* NHL
212Pb-NNV003 (anti-CD37 radioimmunoconjugate)** CLL and other NHL
NNV014 (anti-CD37 ADC)(R&D collaboration)
CLL and other NHL
PARADIGME – Pivotal Phase 2b
Archer-1 – Phase 1b
LYMRIT 37-05 – Phase 1
IND-ready
R&D
RTX – rituximab; DLBCL – diffuse large B-cell lymphoma: SCT – Stem cell transplant; ADC: antibody-drug conjugate; CLL: chronic lymphocytic leukaemia*On hold, refocusing resources towards PARADIGME; **R&D collaboration
R&D
Nordic Nanovector pipeline – Multiple attractive opportunities in NHL
Commercialisation
Pipeline Development
Goal: capture value of Betalutin® in the US; the largest single market
Develop differentiated target product profile to meet requirements of regulatory and reimbursement agencies
Strategy to capture significant value in NHL
77
FL
The slide shows the overall market potential in G7* – Source; Pharmacor Oncology: Non-Hodgkin’s Lymphoma, by Decision Resources Group, 2015 *Germany, France, Italy, Spain, United Kingdom, United States, Japan
c.$2.1B
c.$2.7BDLBCL
Platform Leverage expertise and IP to create long-term value internally and through strategic partnerships
Betalutin® + RTXAccelerate access to 2L FLthrough confirmatory Phase 3 trial
3L R/R FL Single-agent Betalutin®
First-to-market indication
2L R/R FL
R/R DLBCLBetalutin®
To maximize NHL opportunity in largest NHL type
Clinical Development1
3
2
Identify opportunities for ex-US regions
Refine US commercial strategy and deploy launch readiness plan
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
NHL – HIGH UNMET NEED DESPITE AVAILABLE TREATMENTS
NHL – high unmet need despite available treatments
• 7th most common cancer in the US1
• Median age at diagnosis is 67 years1
• Incidence across G7* is 17 per 100,000 per year, resulting in >130,200 new cases in 20142
• Expected to grow by nearly 20% by 2024, as a result of population growth and aging population2
• Market potential expected to reach $28.7 billion by 20263
9
• FL (~20%)• Marginal zone lymphoma (MZL)• Lymphoplasmacytic lymphoma• Chronic lymphocytic leukemia/small-
cell lymphocytic lymphoma (CLL/SLL)
• DLBCL (~40%)• Burkitt lymphoma• Lymphoblastic lymphoma• Mantle cell lymphoma• Primary mediastinal large B-cell lymphoma
Indolent (iNHL)(40% of all NHL)
Aggressive(60% of all NHL)
NHL
T-cell NHLB-cell NHL
85% 15%
1seer.cancer.gov2Pharmacor Oncology: Non-Hodgkin’s Lymphoma, by Decision Resources Group, 2015 3Landscape & Forecast: Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia, by Decision Resources Group, 2017* France, Germany, Italy, Spain, United Kingdom, United States, Japan
FL - shorter remissions with each successive therapy and no cure at present
10Remission RemissionRemissionRemissionRemission
Relapse Relapse Relapse Relapse
Anti-CD20(Rituximab, obinutuzumab)
Anti-CD20(Rituximab, obinutuzumab)
Anti-CD20(Rituximab)
Idelalisib Clinical trials with novel drugs(CAR-T)
Chemotherapy(Bendamustine, CHOP, CVP)
Chemotherapy(Bendamustine, fludarabine, CHOP)
Immunomodulatory agents(Lenalidomide)
Radioimmunotherapy
Rituximab
Radioimmunotherapy
BSC / Palliative therapy
Approx. 16,000 patients Approx. 10,000 patients Approx. 5,000 patientsApprox. 24,000 patients
Followed by:• High dose chemo + Stem Cell Transplant• Allogenic SCT• Rituximab / obinutuzumab maintenance
Followed by:• Rituximab maintenance• Radioimmunotherapy
1st line 3rd line2nd line Later lines
OR
++
+
OR
OR
OR
OR
Treatment regimens including listed options are either approved or recommended by NCCN or ESMO guidelines
Copanlisib
OR
Duvelisib
DLBCL – limited treatment options for patients relapsing after first-line therapy
11
High-dose immunochemotherapy (R-DHAP, R-ESHAP, R-GDP, R-GemOx. R-ICE) followed by:
Autologous Stem CellTransplantation (in some casesAllogeneic SCT)
Salvage immunochemotherapy(R-CEPP, R-CEOP, R-DA-EPOCH, R-GDP, R-GemOx, R-benda)
Approx. 18,000 patients
2nd line
Treatment regimens including listed options are either approved or recommended by NCCN or ESMO guidelines
Transplanteligible
Y
N
30-40%
60-70%
Anti-CD20(Rituximab)
Chemotherapy(CHOP, CEPP, CDOP, DA-EPOCH, CEOP, GCVP)
Approx. 46,000 patients
1st line
+Abicabtagene ciloleucel
Approx. 10,000 patients
3rd line
OR
Tisagenlecleucel
OR
Pixantrone
OR
Radiation therapyOR
Clinical trials with novel drugs
Other drug treatment (brentuximab vedotin, R-lenalidomide, rituximab)
OR
ORClinical trials with novel drugs
NHL – the need for new treatment options
• 40-60% of iNHL patients treated with a RTX-containing regimen are either refractory to therapy (10%) or develop resistance within five years, so having an alternative therapeutic target to CD20 is important
• Relapsed/refractory patients may not tolerate chemotherapy because of age or co-morbidities, so “chemo-free” regimens are in high demand
12
~40% of DLBCL patients relapse following 1L RTX-chemo; 60-70% of these patients fail or are unsuitable for subsequent high-dose chemo + SCT
FL: Five-year overall survival for RTX-refractory patients vs all: 58%1 vs 88%2
1Abdollahi S et al, Blood 2008:1122seer.cancer.gov (2019)3Rivas-Delgado A et al. EHA 2017; abstract 405
59%
5 year PFS3
36%
26%
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
BETALUTIN® – A ONE-TIME TREATMENT FOR NHL PATIENTS
Betalutin®: A novel CD37-targeting radioimmunotherapy
14 1. Flinn IW. Blood 2011; 118: 4007–4008;
• CD37 is highly expressed in B-NHL1
• 177Lu: a low energy β-emitter with a half-life of 6.7 days
• Mechanism of action:
– Internalization and cell death– Crossfire effect targets cells with variable CD37
expression and poorly-vascularized tumour regions
15
Betalutin®
Alternative target to CD20, well suited for NHL patients who progress after RTX-based regimens
Potential synergy from combination with anti-CD20 mAbs and other therapies
Convenience for NHL patients – simple, one-time treatment, QoLConvenience for physicians – ready-to-use, optimised resourcing
Predictable and manageable toxicity*, important for elderly NHL patients who might not be able to tolerate chemotherapy
High and durable response from one-time treatment in heavily pre-treated NHL patients*
* Kolstad A, et al. Abstract 2879, ASH 2018.
Betalutin® is specifically designed as a one-time treatment for NHL: Compelling, unique and differentiated value proposition
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
BETALUTIN® – PROMISING SAFETY AND EFFICACY IN R/R FL
Clinical development optimized to deliver Betalutin®
to FL patients as soon as possible• Objective is to deliver a product with a differentiated target product profile that meets the
requirements of both regulatory and reimbursement agencies
17
LYMRIT 37-01 Phase 1/2a trial
PARADIGMEPivotal, global randomised Phase 2b trial
USFiling
Phase 1
Dose-escalation cohorts to determine the MTD/RDE* of
Betalutin®
Phase 2a
Dose expansion cohorts for confirmatory safety
and exploratory efficacy
74 R/R iNHL patients with a median of 3 prior therapies
All patients received a single administration of Betalutin®
3L FL patients refractory to anti-CD20 therapy
Target is 130 patients at 80-85 sites in approx. 20 countriesPrimary endpoint: ORR
Secondary endpoints: DoR, PFS, OS, Safety, QoL
Complete patient enrolment in 2H 2020
Comparing two dosing regimens with the goal to select the best Betalutin® dosing regimen for filing
Betalutin® + RTX: Accelerate access to 2L FL through confirmatory Phase 3 trial
* Maximum tolerated dose / Recommended dose for expansion
LYMRIT 37-01: Promising safety and efficacy in R/R FL*
18
Patient characteristics (n=74)
• Elderly (median 68 years)
• Heavily pre-treated with advanced-stage disease at baseline
• Primarily FL (n=57) with other NHL types (n=17)
Betalutin® was well tolerated
• Most common grade 3/4 AEs were transient and reversible neutropenia and thrombocytopenia
• Serious AEs occurred in 14 pts (19%)
• No cases of febrile neutropenia, low incidence of platelet transfusion, and no study related deaths
Compelling response rate in FL and MZL** patients from a single administration
ORR CR
All patients (n=74) 61% 28%
All FL patients (n=57) 65% 28%
Arm 1 (40/15) (n=25) 64% 32%
Arm 4 (100/20) (n=16) 69% 25%
FL with ≥2 prior therapies (n=37) 70% 32%
RTX*-refractory FL, ≥2 prior therapies (n=21) 62% 19%
MZL (n=9) 78% 44%
*Kolstad A, et al. Abstract 2879, ASH 2018** MZL – Marginal Zone Lymphoma
Preliminary mDoR (Updated August 2019) • Preliminary analysis shows median duration of response
(mDoR) of 13.5 months (formerly 9.0 months in December 2018). Final data will be presented at the R&D Day.
• Follow-up for mDoR is ongoing
Betalutin® continues to be a novel and effective therapy among 3L FL competitors
19
Betalutin(Phase I/2)
3rd
Line
53%
93%
79%
75%
77%
71%
42%
59%
54%
70%
71%
50%
7%
21%
1%
14%
8%
32%
CR ORR
• All agents are approved based on different phase results as mentioned along with asset• Results from different trials for comparison purpose only and NOT head to head studies • Accelerated Approval basis on Phase II
• # at doses ≥5 mg
Copanlisib*(Marketed)
Idelalisib(Marketed)
ME401(Phase 1b)
Duvelisib*(Marketed)
Kymriah(Phase II)
TazemetostatEZH2m+(Phase II)
REGN1979#
(Phase I)
Parsaclisib(Phase I/II)
Umbralisib(Phase I)
mDOR (months)
Pts.’ Median Age
Route of Administration Mechanism of Action Source
~13.5* (20.7 in CR pts)
68 IV infusion (one-time administration), preceded by 1 RTX and 1 lilotomab CD37-targeting RIT
Kolstad et al, ASH 2018 (37 3L FL pts.); *Latest company update
>12.5 62 Oral, twice daily Pi3k inhibitor Prescribing info(72 patients)
14.1 62 IV infusion (weekly – 3 weeks on and 1 week off) until progression Pi3k inhibitor Prescribing info
(104 patients)
10 64 Oral, twice daily, until disease progression Pi3k inhibitor Prescribing info(83 patients)
N/A 59 (part A66 (part B) Oral, once daily Pi3k inhibitor Forero-Torres et al,
ASH 2017 (4 patients)
8.3 61 Oral, twice daily EZH2 inhibitor Epizyme, ICML 2019(43 patients)
N/A 64.5 Oral, once daily Pi3k inhibitor ASCO 2019(30 patients)
15 (83%) 59 IV infusion of re-engineered autologous T-cells, preceded by leukapheresis and CT CAR-T cell therapy Novartis, ASH 2016
(14 patients)
NR 67 Multiple dose levels of REGN1979;IVAnti-CD20 X Anti-CD3 bispecific antibody
Regeneron Pharma, EHA 2019 (21 pts.)
NR 66 Oral; daily dose; until disease progression or off study Pi3k inhibitor Matthews et al, ASH
2017 (146 pts.)
20
• 81 clinical sites are open for enrolment (as of Aug 21st, 2019)
• An interim analysis for futility is targeted for 1H 2020
PARADIGME: Dose selection aligned with regulatory feedback
Day -14 Day 0
Rituximab375 mg/m2
20MBq/kg Betalutin®
(+ 100mg/m2 llo)(n=65)
15MBq/kg Betalutin®
(+ 40mg llo*)(n=65)
Randomisation Complete patient enrolment 2H 2020
• Patient population: 130 patients with 3L FL who are refractory to anti-CD20 therapy
• Primary endpoint: Overall response rate (ORR)
• Secondary endpoints: Duration of response (DoR), Progression free survival (PFS), Overall survival (OS), Quality of life (QoL)
Filing1H 2021
Interim AnalysisTarget 1H 2020
*Ilo – lilotumab, naked anti-CD37 antibody
• Orphan Drug Designation granted in US and EU in 2014
• Clinical plan for Betalutin ® agreed with FDA in September 2017 (type C meeting)
• Enhance dialogue with regulators to bring Betalutin® to FL patients quicker thanks to:
– Fast-track designation granted in the US in June 2018
– Promising Innovative Medicine (PIM) designation granted in the UK in October 2018
21
Regulatory path focused on expedite product approval
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
BETALUTIN® – ONGOING DEVELOPMENT IN 2L FL
Clinical development strategy to pursue accessto 2L FL indication
• Access significantly larger market opportunity than 3L FL – at present $1.5B
• Strong rationale for combination from preclinical models*
– Betalutin® + RTX significantly inhibited tumour growth and prolonged overall survival
– Hypothesis: Betalutin® reverses downregulation of CD20 expression and RTX resistance
23
LYMRIT 37-01and PARADIGME
Archer-1
Confirmatory Phase 3 studyin 2L FL
(to be discussed with Regulatory authorities)
Leverage US operations and
customer-facing infrastructure
Repetto-Llamazares A et al. Eur J Haematol 2018
Demonstrated synergistic effect of Betalutin® in combination with RTX in a preclinical NHL model
• Betalutin® shown to increase binding of rituximab to NHL cells in vitro and increase uptake of RTX in NHL tumours in vivo
• Strong synergistic effect of combination of Betalutin® and RTX on survival of mice with NHL (Hazard ratio = 0.024, Cox regression)
• Median survival time for combination: >222 days (p < 0.05)
• Median survival time with either treatment alone was 31 - 40 days with RTX or 50 days with Betalutin®
24 Repetto-Llamazares A et al. Eur J Haematol 2018
Survival analysis of nude micewith s.c. Daudi xenografts
Su
rviv
al
• Patient population: 20-25 patients with FL (grade I-IIIA) ≥1 prior regimens
• Primary objective: To evaluate the safety and tolerability of Betalutin® in combination with RTX
• Secondary objective: To evaluate the preliminary anti-tumour activity of combination treatment
• First patient dosed in November 2018
• First safety cohort completed (10 MBq/kg Betalutin®), dose increased (15 MBq/kg) for next 3-6 patients
25
Rituximab375mg/m2
Rituximab375mg/m2
Rituximab375 mg/m2 or 1400 mg s.c.
Q 12 weeks for 2 years or until disease progression
DISCONTINUE
SD, PRor CR
Day -14 Days 7, 14, 21 and 28
PD
Archer-1: Betalutin® + rituximab in R/R FL
Data read-out2H 2020
Day 0
10MBq/kg Betalutin®
(+ 40mg llo)
or
15MBq/kg Betalutin®
(+ 40mg llo)
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
BETALUTIN® – POTENTIAL IN DLBCL
Betalutin® has demonstrated efficacy in preclinical models of DLBCL
27* Melhus et al., EHA annual meeting, Stockholm, 2018.** Pichard, et al. Submitted to Leukemia, 2019.
0
25
50
75
100
0 10 20 30 40 50
Surv
ival
(%)
Time post-xenograft (days)
0
1000
2000
3000
0 10 20 30 40 50
Tum
orvo
lum
e (m
m3 )
Time post-xenograft (days)
NaCl 177Lu-lilotomab (100 MBq/kg)Lilotomab (0.5 mg/kg) 177Lu-cetuximab (125 MBq/kg)
• In vivo therapy of SCID mice with DOHH2 DLBCL xenografts show an improved effect of Betalutincompared with lilotomab and non-specific 177Lu-cetuximab**
28
• Patient population: Up to 24 patients with R/R DLBCL
• Primary objective: Determine maximum tolerated dose (MTD)
• Secondary objectives: Safety and preliminary activity
LYMRIT 37-05: Phase 1 dose-escalation study in R/R DLBCL patients not eligible for SCT
*all patients to receive RTX 375 mg/m2 on day -14
10MBq/kg Betalutin®
(+ 60 mg/m2 llo)(n ≥3)
15MBq/kg Betalutin®
(+ 100 mg/m2 llo)(n ≥3)
10MBq/kg Betalutin®
+ 100 mg/m2 llo(n ≥3)
20MBq/kg Betalutin®
(+ 100 mg/m2 llo)(n ≥3)
Initial data read-out
2H 2019
Expansion Phase with selected dose
20 patients
• No safety issues were identified in the first 3 cohorts
• Patient enrolment completed (July 2019)
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
COMMERCIALISING BETALUTIN® –CAPTURING ITS VALUE IN NHL
Insight from pre-commercial research – defining optimal commercialisation strategy for success
• The value of Betalutin® as a new treatment option in NHL is clearly perceived by stakeholders
– Efficacy is seen as a major strength
– The combination of efficacy, manageable toxicity and convenience of one-time administration makes Betalutin® truly appealing
– Betalutin® targets unsatisfied areas of the market, and will be well positioned to serve unmet needs of patients – elderly with co-morbidities and RTX-refractory
• Analogs’ case studies highlight key strategies to maximise the clinical and commercial potential of Betalutin®
– Pre-launch scientific engagement of thought leaders in NHL centers of excellence on Betalutin’s benefits and positioning
– Well-designed clinical development plan, aligned with health authorities’ feedback
– Robust market access and reimbursement programme
– Optimised referral pathway
– Streamlined manufacturing and distribution via a centralised logistics partner30
Betalutin® – a clear path to commercialisation
• Retain Betalutin® as a wholly owned asset
• Actively participate in its commercialisation in the US
• Explore potential distribution agreements in selected geographies
• Successfully position Betalutin® in first-to-market indication (3L FL)
• Expand in 2L FL with RTX combination therapy
• Leverage US commercial infrastructure to penetrate DLBCL market space
• Maximize product value through life-cycle management
• Target price premium vs. prior radioimmunotherapies
• Align price to that of new agents approved in 3L FL
• Ensure price reflects incremental value to payers, healthcare professionals and patients over alternative treatments
Go-to-market strategy Launch strategy Pricing strategy1 2 3
31
32
We have a thorough understanding of disease state, competitive landscape, patient flow and customer behaviour
• Case study deep dives: Xofigo®, SIR Spheres®, Zevalin®
• Categorised settings of care for licensed administration facilities
• Deep dive into the radiopharmacylandscape
• Research on requirements to become an Authorised User
• Customer segmentation
• Positioning and messaging
• Patient referral pathway
• Patient flow
1:1 Discussions with HaemOncs, RadOncs, NucMeds (n = 190), Health Physicists and Radio-pharmacists (n = 40) Sample included HCPs from private clinics, community hospitals/systems, IDNs and academic centers (approx. 2/3 US, 1/3 EU)
• US pricing and market access research
• EU-4* pricing and market access research
• Reimbursement pathway (US, EU-5**)
1:1 Discussions with Payers (n = 60) Focus on both commercial plans and government health plans in the US (Medicare / Medicaid), and EU-4 (NHS reimbursement systems)
• Qualitative patient research
1:1 Discussions with Patients (n = 22) Focus on patient journey, role of patient and caregivers, buying process, leverage points and barriers for Betalutin®
• Integration of primary / secondary market research data with claims data and other sources to map outpatient physician treatment of FL patients in US community settings
• Distribution and fulfilment strategy research
First four tasks completed 1:1 Discussions with HemOncs, RadOncs, NucMeds, RadioPharms, Industry Trade Experts, Distributors (n = 84)
Secondary Research Payers and PricingQualitative Insights Patient Insights Special Projects
*Germany, France, Italy and Spain**Germany, France, Italy, Spain, United Kingdom
Betalutin® manufacturing and supply chain
• Biological intermediates (lilotomab satetraxetan, lilotomab) and no-carrier added Lutetium-177 are sourced in Europe
• Betalutin® Drug Product is manufactured at the Institute for Energy Technology (IFE; Kjeller, Norway)
• Additional regional manufacturing site in North America scheduled to come on-line after approval
• Logistics supply chain from European production site at launch will secure 48-72 hour delivery to all administration sites – US-based logistics partner will have strong radio-pharmacy network
• Strong internal capabilities overseeing manufacturing, quality and distribution
33
Broad IP protection
Betalutin®
• Composition of matter patent (covers Betalutin®, Humalutin®, uses etc.)
• Expires in 2031*• Approved in several countries
Betalutin® + rituximab• Up-regulation of CD20 by
Betalutin®
• Expires in 2034*• Approved in EU and about
half of the countries
Pre-dosing• Cover different ways of
pre-dosing with lilotomab• Expires in 2037*• Pending in serveral all
countries
Combination patent• Combination of Betalutin®
and Humalutin® withdifferent drug classes
• Expires in 2038*• Pending in all countries
2010 2013 2016 2017
*With 5 years extension possible34
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
PIPELINE
• Collaboration project with Orano Med (formerly AREVA Med)
• NNV003 is a chimeric anti-CD37 mAb developed by Nordic Nanovector
• 212Pb is an alpha-particle emitter with clinically attractive properties
– 10.6 hr half-life; range of alpha-particle is 50-100 µm
• Potential to target chronic lymphocytic lymphoma and other disseminated B-cell tumours
• Safety of 212Pb has been demonstrated in clinical trials*
• Well tolerated with a 90-100% survival rate in preclinical models of Chronic Lymphocytic Leukemia (CLL) and NHL**
36
212Pb-NNV003
NNV003 –chimeric anti-CD37 mAb
Lead-212 payload
*Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.Meredith RF, et al. Am J Clin Oncol. 2018 Jul;41(7):716-721** Saidi, A. et al. Abstract #4422, ASH 2018
Preclinical project: 212Pb-NNV003 A novel targeted alpha therapy for treatment of B-cell malignancies
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
FINANCIALS
Tight cost control; investment focused on clinical development and CMC activities
38
Operating results Distribution of total operating expenses
1H 2019: 77 %
(1H 2018: 72 %)
1H 2019: 23 %
(1H 2018: 28 %)
Development* Administration
* preclinical, clinical, medical affairs, regulatory and CMC activites
-85-77
-96-90
-111-120
-100
-80
-60
-40
-20
0Q2'18 Q3'18 Q4'18 Q1'19 Q2'19
MN
OK
39 ** USD/NOK 7.75 ** USD/NOK 8.51
$ 92M*
$ 61 M**
Cash resources through to mid-2020
• Net cash from operating activities ofnegative NOK 102.2 million
• Net cash flow from investing activities ofNOK 0.2 million
• Net cash flow from financing activities ofNOK 7 million
-71 -71 -60
98
-95-200
-100
0
100
200
Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019
642
570500
440
539 444
0100200300400500600700
Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019
Cash position
• Cash position of NOK 444 million as at end Q2 2019
• The company maintains its guidance that current cash resources are expected to be sufficient to reach mid-2020
(MUSD 83*)
(MUSD 52**)
MN
OK
MN
OK
Net cash flow 1)
1) Net cash flow from operating, investing and financing activities plus/minus currency effect
Q2 2019:
Key shareholders*
40
Top 5 Shareholders % ownershipHealthCap VI L.P. 10.36%Folketrygdfondet 5.65%OM Holding AS 4.57%Nordnet Livsforsikring AS 3.09%DNB Markets 1.67%
Total 20 largest shareholders 39.37%
Total number of shares (fully diluted) 55,113,696
Average traded volume: 136,000 shares
*As of August 26, 2019
Nordic Nanovector ASAKjelsåsveien 168 B, 0884 Oslo, Norwaywww.nordicnanovector.comIR contact: [email protected]
SUMMARY
42
Opportunistically consider partnerships to further enhance shareholder returns
Complete enrolment into PARADIGME to enable BLA filing for Betalutin® with differentiated product profile
Advance clinical development of Betalutin® + RTX combination in 2L FL
Develop and execute commercialisation strategy for Betalutin® in NHL in the US
Selectively extend the company’s pipeline targeting other B-cell malignancies around radioimmunotherapy expertise
Maintain rigorous capital management
Strategic priorities focused on creating shareholder value
Progress clinical development plan with Betalutin® in DLBCL
Key company goals 2019-2021
43
1H 2019 Betalutin® in DLBCL LYMRIT 37-05: Enrolment completed (11 July)
2H 2019 Betalutin® in DLBCL LYMRIT 37-05: Data read-out
1H 2020
Betalutin® in DLBCL LYMRIT 37-05: First patient dosed (Expansion cohort)
Betalutin® in 3L FL PARADIGME: Interim analysis for futility
Betalutin® + rituximab in 2L FL Archer-1: Enrolment completed
2H 2020Betalutin® + rituximab in 2L FL Archer-1: Data read-out
Betalutin® in 3L FL PARADIGME: Enrolment completed (data read-out to follow a few months later)
1H 2021 Betalutin® in 3L FL Regulatory filing